Research reportAn immunochemical analysis of the human nuclear phosphoprotein p53: New monoclonal antibodies and epitope mapping using recombinant p53
References (24)
- et al.
The p53 protooncogene can act as a suppressor of transformation
Cell
(1989) - et al.
p53 immunostaining is a marker of malignancy in diagnostic cytopathology
Lancet
(1991) - et al.
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Lancet
(1990) - et al.
Characterization of human p53 antigens employing primate specific monoclonal antibodies
Virology
(1983) - et al.
Suppression of human colorectal carcinoma cell growth by wild-type p53
Science
(1990) - et al.
Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression
Eur. J. Biochem.
(1986) - et al.
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
Oncogene
(1990) - et al.
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies
Oncogene
(1991) - et al.
Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer
Oncogene
(1991) - et al.
p53 expression in breast cancer
Int. J. Cancer
(1988)
Genetic mechanism of tumor suppression by the human p53 gene
Science
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form
EMBO J.
Cited by (583)
Dual redox labeling of DNA as a tool for electrochemical detection of p53 protein-DNA interactions
2019, Analytica Chimica ActaCitation Excerpt :This type of binding is performed by a basic segment of the protein C-terminus (C-terminal DNA binding site, CTDBS) [32]. Use of monoclonal antibodies whose epitopes coincide with the CTDBS (such as Bp53–10.1) enables to modulate the mode of p53 DNA binding in the sense of blocking the CTDBS, which disables the structure-selective DNA binding of p53 but enhances its ability to bind DNA in a sequence-specific manner [33,37]. Thus, apart from the p53 importance in organisms’ defense against cancer development, its ability to bind DNA in various modes, ranging from non-specific interactions to sequence-specific DNA binding, makes it a convenient model protein for development of a novel approach for dual detection of protein-DNA interactions based on redox-labeled DNA probes.
Expression of cell cycle proteins according to HPV status in oral squamous cell carcinoma affecting young patients: a pilot study
2018, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyCitation Excerpt :Tumor suppressor proteins negatively modulate neoplastic transformation, inhibiting progression through cell cycle checkpoints, where they exhibit changes in DNA and others promote apoptosis.32 The tumor suppressor protein p53 has the regulatory function of avoiding duplication of damage to DNA that regulates the cell cycle, DNA repair, and apoptosis, as well as inhibiting tumor formation.38 Protein p16 is encoded by the gene CDKN2 A CDK, which acts by binding to CDK4/CDK6, preventing their interaction with cyclin D.
Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study
2017, American Journal of Obstetrics and GynecologyImmunoassays of chemically modified polysaccharides, glycans in glycoproteins and ribose in nucleic acids
2017, Analytica Chimica Acta